Does Rallies show Form 4 insider transactions for CRVO?

Yes. Rallies tracks CRVO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CRVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRVO. It does not provide personalized investment advice.

CRVO (CervoMed Inc. Common Stock) Stock Analysis - Insider Trades

CervoMed Inc. Common Stock (CRVO) is a publicly traded Healthcare sector company. As of May 21, 2026, CRVO trades at $3.24 with a market cap of $28.15M and a P/E ratio of -1.08. CRVO moved +12.80% today. Year to date, CRVO is -58.51%; over the trailing twelve months it is -63.10%. Its 52-week range spans $1.80 to $16.94. Analyst consensus is strong buy with an average price target of $20.80. Rallies surfaces CRVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CRVO stock inside the company?

Recent CRVO insider activity includes Winton Matthew bought 1.50K, ELDER WILLIAM ROBERT bought 2.50K, Winton Matthew bought 3.50K, Gregoire Sylvie bought 10.79K, and Gregoire Sylvie bought 10.81K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CRVO Key Metrics

Key financial metrics for CRVO
Metric	Value
Price	$3.24
Market Cap	$28.15M
P/E Ratio	-1.08
EPS	$-2.98
Dividend Yield	0.00%
52-Week High	$16.94
52-Week Low	$1.80
Volume	0
Avg Volume	0
Revenue (TTM)	$4.01M
Net Income	$-26.97M
Gross Margin	0.00%

Recent CRVO Insider Trades

Winton Matthew bought 1.50K (~$11.93K) on Nov 18, 2025.
ELDER WILLIAM ROBERT bought 2.50K (~$20.80K) on Nov 18, 2025.
Winton Matthew bought 3.50K (~$29.50K) on Nov 17, 2025.
Gregoire Sylvie bought 10.79K (~$91.31K) on Nov 17, 2025.
Gregoire Sylvie bought 10.81K (~$91.43K) on Nov 17, 2025.

Latest CRVO News

CervoMed’s Neflamapimod Yields 1.11-Point CDR-SB Benefit in DLB Patients — Mar 19, 2026
CervoMed’s Neflamapimod Joins UK EXPERTS-ALS Trial with 35-80 Patient Cohorts — Feb 18, 2026

CRVO Analyst Consensus

5 analysts cover CRVO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.80.

Common questions about CRVO

Who is trading CRVO stock inside the company?: Recent CRVO insider activity includes Winton Matthew bought 1.50K, ELDER WILLIAM ROBERT bought 2.50K, Winton Matthew bought 3.50K, Gregoire Sylvie bought 10.79K, and Gregoire Sylvie bought 10.81K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CRVO?: Yes. Rallies tracks CRVO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CRVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRVO. It does not provide personalized investment advice.